AMLX
Amylyx Pharmaceuticals Inc

2,188
Loading...
Loading...
News
all
press releases
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a cash runway until the end of 2026.
Stocktwits·1mo ago
News Placeholder
More News
News Placeholder
Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder
The decision to discontinue the program was made after AMX0035 did not show differences compared to placebo on primary or secondary outcomes at week 24 in a mid-stage trial.
Stocktwits·1mo ago
News Placeholder
Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial
The company is advancing the treatment into a Phase 3 study with results expected in 2026.
Stocktwits·3mo ago
News Placeholder
Citi initiates coverage on biotech amid improving sentiment in sector
Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.
investing.com·4mo ago
News Placeholder
Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?
Zacks·4mo ago
News Placeholder
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will participate in the following upcoming investor conferences, which are being conducted...
Business Wire·7mo ago
News Placeholder
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025. Amylyx senior management team will...
Business Wire·7mo ago
News Placeholder
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that Amylyx management will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference. The...
Business Wire·8mo ago
News Placeholder
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial...
Business Wire·8mo ago
News Placeholder
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price...
Business Wire·9mo ago

Latest AMLX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.